論文

査読有り 国際誌
2018年6月

Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.

Oncology letters
  • Hisato Yoshida
  • ,
  • Hitoshi Yoshimura
  • ,
  • Shinpei Matsuda
  • ,
  • Takashi Ryoke
  • ,
  • Tamotsu Kiyoshima
  • ,
  • Motohiro Kobayashi
  • ,
  • Kazuo Sano

15
6
開始ページ
8627
終了ページ
8634
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3892/ol.2018.8399
出版者・発行元
Spandidos Publications

Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α-SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.

リンク情報
DOI
https://doi.org/10.3892/ol.2018.8399
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29805597
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950523